Core Insights - The report highlights the significant growth potential in the peripheral artery balloon dilation catheter market, driven by the increasing prevalence of peripheral vascular diseases and advancements in interventional procedures [2][6]. Group 1: Industry Overview - Peripheral vascular diseases encompass all conditions affecting blood vessels outside the heart and brain, primarily categorized into peripheral artery disease and peripheral venous disease [2]. - Peripheral artery disease accounts for approximately 40% of peripheral vascular diseases, with 80% of cases occurring in the lower limbs [3]. - The prevalence of peripheral artery disease in China is projected to rise from 49.464 million in 2019 to 55.437 million by 2024, with a compound annual growth rate (CAGR) of 2.3% [3]. Group 2: Market Size and Growth - The market for peripheral artery balloon dilation catheters in China is expected to grow from 390 million yuan in 2019 to 1.14 billion yuan by 2024, reflecting a CAGR of 23.8% [6]. - The functional balloon catheter market is anticipated to expand from 30 million yuan in 2019 to 150 million yuan by 2024, with a CAGR of 35.9% [6]. Group 3: Clinical Applications and Technology - Peripheral artery balloon dilation catheters are widely used for treating various peripheral artery diseases, including atherosclerosis and occlusive arterial disease, which can lead to severe symptoms such as pain and gangrene [5]. - The development of interventional procedures has made vascular intervention a preferred treatment option, with a broad application of devices such as balloons, stents, and plaque removal systems [4].

Core Viewpoint - Guangdong Boma Medical Technology Co., Ltd. has received acceptance for its IPO on the Shenzhen Stock Exchange's ChiNext board, aiming to raise 1.7 billion RMB for its operations in the high-performance vascular interventional medical device sector [1]. Group 1: Company Overview - Boma Medical specializes in the research, production, and global sales of high-performance vascular interventional medical devices, positioning itself as a leading provider of complex vascular disease intervention solutions [1]. - The company has developed a comprehensive product matrix with over 50 product series, covering critical areas such as coronary intervention, peripheral intervention, neurointervention, blood dialysis pathways, and interventional accessories [1]. Group 2: Market Presence - Boma Medical's products are marketed in over 100 countries and regions, serving thousands of hospitals and medical centers globally, establishing a strong brand image in the vascular interventional medical device market [2]. - The company has maintained a stable and rapid growth trajectory in both domestic and international markets, with a projected compound annual growth rate (CAGR) of 48.98% in revenue from 2022 to 2024 [2]. Group 3: Financial Performance - In terms of market share, Boma Medical is projected to hold 9.6% of the coronary balloon dilation catheter market in China, ranking fourth overall and first among domestic brands, and 4.7% of the peripheral artery balloon dilation catheter market, ranking fifth [3]. - The company reported revenues of approximately 207 million RMB, 335 million RMB, 460 million RMB, and 303 million RMB for the years 2022, 2023, 2024, and the first half of 2025, respectively, with net profits showing a significant turnaround from a loss of 36 million RMB in 2022 to a profit of 35.6 million RMB in the first half of 2025 [3][4]. Group 4: Fundraising and Investment Plans - The funds raised from the IPO will be allocated to various projects, including the establishment of a global headquarters, production base upgrades, and research and development for interventional medical devices, with a total planned investment of approximately 1.814 billion RMB [3].